Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | REN | P00797 | 3/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334003 | 1.00 | HDAC3 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL334245 | 0.89 | RAB9A (0.47) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5049488 | 0.89 | RAB9A (0.47) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL334005 | 0.89 | HDAC3 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL335155 | 0.79 | TDP1 (0.45) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL334598 | 0.79 | TDP1 (0.44) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL334595 | 0.79 | TDP1 (0.44) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL334597 | 0.79 | TDP1 (0.44) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL334596 | 0.79 | TDP1 (0.44) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL334246 | 0.78 | RAB9A (0.47) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097582-B2 | Peptide derivatives useful as antimicrobial agents and for treating wounds | NEOBIOTICS AB (SE) | 2012-01-17 | — | — | US | disclosed |
| US-20100247648-A1 | ANTIMICROBIAL COMPOUNDS | NEOBIOTICS AB (SE) | 2010-09-30 | — | — | US | disclosed |
| US-7691805-B2 | Antimicrobial compounds | NEOBIOTICS AB (SE) | 2010-04-06 | — | — | US | disclosed |
| US-20090118198-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | ZULA DIAGNOSTICS AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20080255055-A1 | Use of Derivatives of Dipeptides for the Manufacture of of a Medicament for the Treamtent of Microbial Infections | NEOBIOTICS AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20060116327-A1 | Dipeptide derivatives with active agents to formulate one composition to reduce, eliminate more than one microorganism; effect against a broad spectrum of microorganisms; mechanism of action on pathogen may be on a basic level; low probability for developing resistance | NEOBIOTICS AB (SE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116327-A1 | Dipeptide derivatives with active agents to formulate one composition to reduce, eliminate more than one microorganism; effect against a broad spectrum of microorganisms; mechanism of action on pathogen may be on a basic level; low probability for developing resistance | ARG1, ARGLU1, VIP | HDAC3 1463/4885HDAC4 1525/4885HDAC1 892/4885 |
| US-20080255055-A1 | Use of Derivatives of Dipeptides for the Manufacture of of a Medicament for the Treamtent of Microbial Infections | VIP, ARG1, PEPD | HDAC3 1867/4885HDAC4 2044/4885HDAC1 1355/4885 |
| US-20090118198-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | VIP, NGLY1, ARG1 | HDAC3 4133/4885HDAC4 3357/4885HDAC1 2589/4885 |
| US-20100247648-A1 | ANTIMICROBIAL COMPOUNDS | ARG1, C1R, ARG2 | HDAC3 318/4885HDAC4 734/4885HDAC1 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.